Understanding how ARNT and its partners control cancer-related cell signals
Official title: Structural, Chemical, And Cellular Probing of a New Anticancer Target: HIF-Coactivator Complexes
Funded at City College of New York · NIH-11413610 · Data updated 2026-11-12
A team will study how ARNT and its partner proteins interact, with the goal of finding ways to regulate these interactions that are linked to cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | City College of New York NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 26, 2008 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $193,497 |
| NIH project number | 5U54CA132378-18 |
| Project ID | NIH-11413610 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients whose cancers show ARNT/HIF pathway involvement or whose tumors overexpress HIF isoforms.
✕Less likely to help
Patients without tumors associated with HIF/ARNT pathway changes may not benefit directly from this research.
What this research studies
This project looks at how ARNT and its coactivators form complexes that control cell responses to low oxygen and toxins, which are often altered in cancer. Researchers will use structural biology and biophysical methods to map the interfaces and test small molecules that can modulate these interactions. The work combines expertise from two labs to pursue a multi-pronged approach, including cryo-EM and other assays, to understand how these protein complexes form and function. If successful, the findings could guide the development of new cancer therapies targeting these protein interactions.
Why it matters
Potential benefit: If the approach succeeds, it could lead to new strategies to treat cancers linked to hypoxia and ARNT pathway deregulation.
How similar studies have gone: Preliminary data and prior work support feasibility in studying ARNT complexes and small-molecule regulators, indicating a promising but early-stage approach.
Where this research is happening
-
City College of New York
New York, United States Active
Researchers
- Principal investigator: Gardner, Kevin H — City College of New York
- Study coordinator: Gardner, Kevin H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.